Summary

Nocturia Market – Scope of Report
TMR’s report on the global nocturia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nocturia market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nocturia market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the nocturia market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nocturia market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nocturia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nocturia market.

The report delves into the competitive landscape of the global nocturia market. Key players operating in the global nocturia market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nocturia market profiled in this report.

Key Questions Answered in Global nocturia Market Report
• What is the sales/revenue generated by nocturia across all regions during the forecast period?
• What are the opportunities in the global nocturia market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Nocturia Market – Research Objectives and Research Approach
The comprehensive report on the global nocturia market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nocturia market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nocturia market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Nocturia Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Nocturia Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product /Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Nocturia Market Analysis and Forecast, by Drug Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Type, 2020-2034
        6.3.1. Anticholinergic Drugs
        6.3.2. Desmopressin
        6.3.3. Antibiotics
        6.3.4. Antispasmodic
        6.3.5. Others
    6.4. Market Attractiveness Analysis, by Drug Type
7. Global Nocturia Market Analysis and Forecast, by Indication Type
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Indication Type, 2020-2034
        7.3.1. Mixed Nocturia
        7.3.2. Low Nocturnal Bladder Capacity
        7.3.3. Nocturnal Polyuria
    7.4. Market Attractiveness Analysis, by Indication Type
8. Global Nocturia Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2020-2034
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Nocturia Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2020-2034
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Nocturia Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Drug Type, 2020-2034
        10.3.1. Anticholinergic Drugs
        10.3.2. Desmopressin
        10.3.3. Antibiotics
        10.3.4. Antispasmodic
        10.3.5. Others
    10.4. Market Value Forecast, by Indication Type, 2020-2034
        10.4.1. Mixed Nocturia
        10.4.2. Low Nocturnal Bladder Capacity
        10.4.3. Nocturnal Polyuria
    10.5. Market Value Forecast, by Distribution Channel, 2020-2034
        10.5.1. Hospital Pharmacies
        10.5.2. Retail Pharmacies
        10.5.3. Online Pharmacies
    10.6. Market Value Forecast, by Country, 2020-2034
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Drug Type
        10.7.2. By Indication Type
        10.7.3. By Distribution Channel
        10.7.4. By Country
11. Europe Nocturia Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Drug Type, 2020-2034
        11.3.1. Anticholinergic Drugs
        11.3.2. Desmopressin
        11.3.3. Antibiotics
        11.3.4. Antispasmodic
        11.3.5. Others
    11.4. Market Value Forecast, by Indication Type, 2020-2034
        11.4.1. Mixed Nocturia
        11.4.2. Low Nocturnal Bladder Capacity
        11.4.3. Nocturnal Polyuria
    11.5. Market Value Forecast, by Distribution Channel, 2020-2034
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Type
        11.7.2. By Indication Type
        11.7.3. By Distribution Channel
        11.7.4. By Country/Sub-region
12. Asia Pacific Nocturia Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Drug Type, 2020-2034
        12.3.1. Anticholinergic Drugs
        12.3.2. Desmopressin
        12.3.3. Antibiotics
        12.3.4. Antispasmodic
        12.3.5. Others
    12.4. Market Value Forecast, by Indication Type, 2020-2034
        12.4.1. Mixed Nocturia
        12.4.2. Low Nocturnal Bladder Capacity
        12.4.3. Nocturnal Polyuria
    12.5. Market Value Forecast, by Distribution Channel, 2020-2034
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Type
        12.7.2. By Indication Type
        12.7.3. By Distribution Channel
        12.7.4. By Country/Sub-region
13. Latin America Nocturia Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Drug Type, 2020-2034
        13.3.1. Anticholinergic Drugs
        13.3.2. Desmopressin
        13.3.3. Antibiotics
        13.3.4. Antispasmodic
        13.3.5. Others
    13.4. Market Value Forecast, by Indication Type, 2020-2034
        13.4.1. Mixed Nocturia
        13.4.2. Low Nocturnal Bladder Capacity
        13.4.3. Nocturnal Polyuria
    13.5. Market Value Forecast, by Distribution Channel, 2020-2034
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Type
        13.7.2. By Indication Type
        13.7.3. By Distribution Channel
        13.7.4. By Country/Sub-region
14. Middle East & Africa Nocturia Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Drug Type, 2020-2034
        14.3.1. Anticholinergic Drugs
        14.3.2. Desmopressin
        14.3.3. Antibiotics
        14.3.4. Antispasmodic
        14.3.5. Others
    14.4. Market Value Forecast, by Indication Type, 2020-2034
        14.4.1. Mixed Nocturia
        14.4.2. Low Nocturnal Bladder Capacity
        14.4.3. Nocturnal Polyuria
    14.5. Market Value Forecast, by Distribution Channel, 2020-2034
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Type
        14.7.2. By Indication Type
        14.7.3. By Distribution Channel
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2023)
    15.3. Company Profiles
        15.3.1. AbbVie Inc.
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Vantia Therapeutics
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Astellas Pharma Inc.
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Urigen Pharmaceuticals Inc.
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Sumitomo Pharma Co., Ltd.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Ferring Pharmaceuticals
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Glenmark Pharmaceuticals
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Teva Pharmaceutical Industries Ltd.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Avadel Pharmaceuticals plc
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview